Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Ovarian Neoplasms × durvalumab × Clear all

Phase

Status

Sponsor Class

OTHER 15 INDUSTRY 5 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrent Squamous Cell Lung Carcinoma 3 Prostatic Neoplasms 2 Colorectal Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Solid Malignancies 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Lung Cancer Metastatic 1 Esophageal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Advanced Rare Tumours 1

Interventions

Paclitaxel 22 Carboplatin 20 Cisplatin 11 Topotecan 6 Taxes 5 Gemcitabine 5 Docetaxel 5 Doxorubicin 4 Ifosfamide 3 Etoposide 3 Cyclophosphamide 3 Chemotherapy, Adjuvant 3 rubitecan 2 paclitaxel poliglumex 2 liposomal doxorubicin 2 Surgical Procedures, Operative 2 Psychiatric Rehabilitation 2 Polymerase Chain Reaction 2 Filgrastim 2 Erlotinib Hydrochloride 2 Bevacizumab 2 vandetanib 1 trioctyl phosphine oxide 1 toripalimab 1 sargramostim 1 rilotumumab 1 pegfilgrastim 1 oregovomab 1 motesanib diphosphate 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04918186 2026-02-12

IPROC

Canadian Cancer Trials Group

Phase 2 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡